Expression of selected long non-coding RNAs in gastric cancer cells treated with coumarin: Possible mechanisms for anti-cancer activity

Pathol Res Pract. 2023 Dec:252:154914. doi: 10.1016/j.prp.2023.154914. Epub 2023 Oct 31.

Abstract

Long non-coding RNAs (lncRNAs) can be utilized as prognostic indicators of gastric cancer since they can affect several cancer-related processes. Coumarin is a natural product with some useful anti-cancer properties. Here, we measured the expression of selected lncRNAs (RuPAR, SNHG6, CASC11, and their targets, miR-340-5p, p21, E-cadherin, and CDK1) in AGS gastric cancer cells treated with coumarin. MTT test has been utilized for assessing the AGS cells' cell viability after exposure to coumarin. The expression of the lncRNAs (RuPAR, SNHG6, and CASC11) and miR-340-5p was evaluated via qRT-PCR. Western blot analysis has been utilized to determine changes in p21, E-cadherin, and CDK1 expression. Coumarin decreased AGS viability in a dose-dependent manner. The coumarin treated cells had lower levels of the mRNAs known to be targets of lncRNAs SNHG6 and CASC11 compared to control. Additionally, the coumarin group had increased levels of lncRNA RuPAR expression when compared with the control group. Some lncRNA targets, including p21, E-cadherin, and CDK1, showed lower expression in the coumarin group compared to the control by Western blotting. Coumarin could be a promising pharmacological candidate to be included in gastric cancer treatment regimens because it modulates lncRNAs and their targets.

Keywords: CASC11; Coumarin; Gastric cancer; Long non-coding RNAs; MiR-340–5p; RuPAR; SNHG6.

MeSH terms

  • Cadherins / genetics
  • Cell Proliferation / genetics
  • Coumarins / pharmacology
  • Humans
  • MicroRNAs* / genetics
  • RNA, Long Noncoding* / metabolism
  • Stomach Neoplasms* / drug therapy
  • Stomach Neoplasms* / genetics

Substances

  • RNA, Long Noncoding
  • MicroRNAs
  • Cadherins
  • Coumarins
  • MIRN340 microRNA, human